Venrock Healthcare Capital Partners III, L.P. 13D and 13G filings for Terns Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:51 pm Sale | 2024-09-30 | 13G | Terns Pharmaceuticals, Inc. TERN | Venrock Healthcare Capital Partners III, L.P. | 3,516,889 4.990% | -980,228 (-21.80%) | Filing |
| 2024-02-14 8:38 pm Purchase | 2023-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | Venrock Healthcare Capital Partners III, L.P. | 4,497,117 7.300% | 789,226 (+21.29%) | Filing |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | Venrock Healthcare Capital Partners III, L.P. | 3,707,891 7.700% | 641,650 (+20.93%) | Filing |
| 2022-08-26 7:24 pm Purchase | 2022-08-16 | 13G | Terns Pharmaceuticals, Inc. TERN | Venrock Healthcare Capital Partners III, L.P. | 3,066,241 8.200% | 3,066,241 (New Position) | Filing |